Finance

Beta
Lists
128940:KRX
Hanmi Pharm Co Ltd
â‚©411,000.00
0.00%
(0.00) 1D
Jun 12, 3:30:30 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 128940...
Open
â‚©422,500
High
â‚©434,500
Low
â‚©409,000
Mkt. cap
5.27T
Avg. vol.
178.65K
Volume
106.24K
Dividend
0.49%
Quarterly dividend
â‚©500
Ex-dividend date
Mar 30, 2026
P/E ratio
30.25
52-wk high
â‚©647,000
52-wk low
â‚©267,500
EPS
â‚©13,587
Shares outstanding
12.81M
No. of employees
2K
Open
â‚©422,500
High
â‚©434,500
Low
â‚©409,000
Mkt. cap
5.27T
Avg. vol.
178.65K
Volume
106.24K
Dividend
0.49%
Quarterly dividend
â‚©500
Ex-dividend date
Mar 30, 2026
P/E ratio
30.25
52-wk high
â‚©647,000
52-wk low
â‚©267,500
EPS
â‚©13,587
Shares outstanding
12.81M
No. of employees
2K
News stories
From sources across the web
Profile
Hanmi Pharm Co., Ltd. is a South Korean pharmaceutical company that is headquartered in Seoul. Wikipedia
About Hanmi Pharm Co Ltd
CEO-
Employees2.34K
Founded1973
Headquarters-
SectorPharmaceutical industry
Websitehanmi.co.kr
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
361.28B
362.35B
432.96B
392.93B
Cost of goods sold
156.54B
156.75B
172.48B
175.64B
Cost of revenue
156.54B
156.75B
172.48B
175.64B
Research and development expenses
44.05B
54.65B
51.66B
57.12B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
100.25B
95.88B
125.55B
106.52B
Operating expense
146.90B
153.33B
205.73B
171.55B
Total operating expenses
303.44B
310.08B
378.22B
347.19B
Operating income
57.84B
52.27B
54.74B
45.74B
Other non operating income
-607.61M
-1.73B
664.20M
2.62B
EBT including unusual items
49.55B
52.26B
58.49B
55.38B
EBT excluding unusual items
49.63B
51.55B
57.99B
55.26B
Income tax expense
6.54B
6.85B
4.43B
4.30B
Effective tax rate
13.20%
13.10%
7.58%
7.76%
Other operating expenses
-
-
-
-
Net income
38.70B
40.13B
48.12B
45.49B
Net profit margin
10.71%
11.07%
11.11%
11.58%
Earnings per share
-
-
-
-
Interest and investment income
1.48B
1.67B
2.51B
2.62B
Interest expense
-4.30B
-3.94B
-3.65B
-3.41B
Net interest expenses
-2.82B
-2.27B
-1.14B
-783.67M
Depreciation and amortization charges
-
-
-
-
EBITDA
82.30B
76.84B
80.03B
70.44B
Gain or loss from assets sale
32.74M
-13.32M
-39.36M
3.68M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer